July 11 (UPI) -- The White House said Thursday that it was abandoning its proposed rule that would have banned drug price rebates collected by pharmacy benefit managers.
The rule, one that the Trump administration had hailed as a move to bring down prescription drug costs, was supported by large pharmaceutical companies, who have blamed the rebates to managers for the high cost of drugs in the United States.